journal
MENU ▼
Read by QxMD icon Read
search

Gynecologic Oncology

journal
https://www.readbyqxmd.com/read/28545689/time-trends-in-the-incidence-of-hysterectomy-corrected-overall-type-1-and-type-2-endometrial-cancer-in-denmark-1978-2014
#1
Mette Tuxen Faber, Kirsten Frederiksen, Allan Jensen, Peter Bo Aarslev, Susanne K Kjaer
OBJECTIVE: To investigate time trends in the incidence of overall, type 1 and type 2 endometrial cancer in Denmark 1978-2014, correcting for hysterectomy. METHODS: Based on the Danish Cancer Registry and the Danish National Patient Registry we calculated hysterectomy-corrected incidence rates of overall, type 1 and type 2 endometrial cancer. Separate analyses for women <55years (defined as pre- and perimenopausal age) and women aged ≥55years (defined as postmenopausal age) and analyses allowing for different time trends before and after the study period midyear 1996 were performed...
May 23, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28545688/quinacrine-in-endometrial-cancer-repurposing-an-old-antimalarial-drug
#2
Eleftheria Kalogera, Debarshi Roy, Ashwani Khurana, Susmita Mondal, Amy L Weaver, Xiaoping He, Sean C Dowdy, Viji Shridhar
OBJECTIVE: Generate preclinical data on the effect of quinacrine (QC) in inhibiting tumorigenesis in endometrial cancer (EC) in vitro and explore its role as an adjunct to standard chemotherapy in an EC mouse model. METHODS: Five different EC cell lines (Ishikawa, Hec-1B, KLE, ARK-2, and SPEC-2) representing different histologies, grades of EC, sensitivity to cisplatin and p53 status were used for the in vitro studies. MTT and colony formation assays were used to examine QC's ability to inhibit cell viability in vitro...
May 22, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28545687/synergistic-effect-of-mek-inhibitor-and-metformin-combination-in-low-grade-serous-ovarian-cancer
#3
Ismail Mert, Jasdeep Chhina, Ghassan Allo, Jing Dai, Shelly Seward, Mark S Carey, Marta Llaurado, Shailendra Giri, Ramandeep Rattan, Adnan R Munkarah
OBJECTIVE: Low-grade serous ovarian cancer (LGSOC) constitutes 5-8% of epithelial ovarian cancers and is refractory to chemotherapy. We and others have shown metformin to cause significant growth inhibition in high-grade ovarian cancer both in vitro and in vivo. Here, we aimed to analyze if metformin was effective in inhibiting proliferation of LGSOC alone and in combination with MEK inhibitor. METHODS: Three LGSOC lines (VOA1056, VOA1312 and VOA5646) were treated with metformin, trametinib or 2-deoxyglucose (2DG) alone or in combination with metformin...
May 22, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28536037/identification-of-molecular-targets-in-vulvar-cancers
#4
Marguerite L Palisoul, Mary M Mullen, Rebecca Feldman, Premal H Thaker
OBJECTIVES: To identify molecular alterations that contribute to vulvar cancer pathogenesis with the intent of identifying molecular targets for treatment. METHODS: After retrospective analysis of a database of molecularly-profiled gynecologic cancer patients, 149 vulvar cancer patients were included and tested centrally at a CLIA laboratory (Caris Life Sciences, Phoenix, AZ). Tests included one or more of the following: gene sequencing (Sanger or next generation sequencing [NGS]), protein expression (immunohistochemistry [IHC]), and gene amplification (C/FISH)...
May 20, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28532856/implementation-of-a-referral-to-discharge-glycemic-control-initiative-for-reduction-of-surgical-site-infections-in-gynecologic-oncology-patients
#5
Laura Hopkins, Jennifer Brown-Broderick, James Hearn, Janine Malcolm, James Chan, Wendy Hicks-Boucher, Filomena De Sousa, Mark C Walker, Sylvain Gagné
OBJECTIVE(S): To evaluate the frequency of surgical site infections before and after implementation of a comprehensive, multidisciplinary perioperative glycemic control initiative. STUDY METHODS: As part of a CUSP (Comprehensive Unit-based Safety Program) initiative, between January 5 and December 18, 2015, we implemented comprehensive, multidisciplinary glycemic control initiative to reduce SSI rates in patients undergoing major pelvic surgery for a gynecologic malignancy ('Group II')...
May 20, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28532858/ovarian-granulosa-cell-tumor-a-national-cancer-database-study
#6
Brandon-Luke L Seagle, Phoebe Ann, Sharlay Butler, Shohreh Shahabi
OBJECTIVE: To provide prognostic information from a large cohort of women with granulosa cell tumor we analyzed the National Cancer Database. METHODS: We performed an observational retrospective cohort analysis of 2680 women with ovarian granulosa cell tumor from the 1998-2013 National Cancer Database. Kaplan-Meier and multivariable Cox proportional-hazards survival analyses were performed for the overall cohort and propensity score matched cohorts to examine the association of surgical staging and adjuvant chemotherapy with survival...
May 19, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28532857/high-stathmin-expression-is-a-marker-for-poor-clinical-outcome-in-endometrial-cancer-an-nrg-oncology-group-gynecologic-oncology-group-study
#7
Henry D Reyes, Jeffrey Miecznikowski, Jesus Gonzalez-Bosquet, Eric J Devor, Yuping Zhang, Kristina W Thiel, Megan I Samuelson, Megan McDonald, Jean-Marie Stephan, Parviz Hanjani, Saketh Guntupalli, Krishnansu S Tewari, Floor Backes, Nilsa Ramirez, Gini F Fleming, Virginia Filiaci, Michael J Birrer, Kimberly K Leslie
OBJECTIVE: Gynecologic Oncology Group (GOG) 177 demonstrated that addition of paclitaxel to a backbone of adriamycin/cisplatin improves overall survival (OS) and progression-free survival (PFS) for patients with advanced or recurrent endometrial cancer. Using patient specimens from GOG-177, our objective was to identify potential mechanisms underlying the improved clinical response to taxanes. Stathmin (STMN1) is a recognized poor prognostic marker in endometrial cancer that functions as a microtubule depolymerizing protein, allowing cells to transit rapidly through mitosis...
May 19, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28528918/a-prospective-validation-study-of-sentinel-lymph-node-mapping-for-high-risk-endometrial-cancer
#8
Pamela T Soliman, Shannon N Westin, Shayan Dioun, Charlotte C Sun, Elizabeth Euscher, Mark F Munsell, Nicole D Fleming, Charles Levenback, Michael Frumovitz, Pedro T Ramirez, Karen H Lu
OBJECTIVE: Sentinel lymph node (SLN) mapping continues to evolve in the surgical staging of endometrial cancer (EC). The purpose of this trial was to identify the sensitivity, false negative rate (FNR) and FN predictive value (FNPV) of SLN compared to complete pelvic and para-aortic lymphadenectomy (LAD) in women with high-risk EC. METHODS: Women with high-risk EC (grade 3, serous, clear cell, carcinosarcoma) were enrolled in this prospective surgical trial. All patients underwent preoperative PET/CT and intraoperative SLN biopsy followed by LAD...
May 18, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28528917/pazopanib-gw786034-and-cyclophosphamide-in-patients-with-platinum-resistant-recurrent-pre-treated-ovarian-cancer-results-of-the-pacovar-trial
#9
C Dinkic, M Eichbaum, M Schmidt, E M Grischke, G Gebauer, H C Fricke, F Lenz, M Wallwiener, F Marme, A Schneeweiss, C Sohn, J Rom
PURPOSE: The prognosis is poor for patients with recurrent, platinum-resistant epithelial ovarian cancer (EOC). Evidence suggests that antiangiogenic treatment modalities could play a major role in EOC. A combined therapy consisting of the investigational oral antiangiogenic agent pazopanib and metronomic oral cyclophosphamide may offer a well-tolerable treatment option to patients with recurrent, previously treated EOC. PATIENTS AND METHODS: This study was designed as a multicenter phase I trial evaluating the optimal dose as well as activity and tolerability of pazopanib with metronomic cyclophosphamide in the treatment of patients with recurrent, platinum-resistant, previously treated ovarian, peritoneal, or fallopian tube cancer...
May 18, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28528916/indications-for-and-complications-of-transfusion-and-the-management-of-gynecologic-malignancies
#10
REVIEW
Paulina Cybulska, Cheryl Goss, William P Tew, Rekha Parameswaran, Yukio Sonoda
Anemia, which is highly prevalent in oncology patients, is one of the most established negative prognostic factors for several gynecologic malignancies. Multiple factors can cause or contribute to the development of anemia in patients with gynecologic cancers; these factors include blood loss (during surgery or directly from the tumor), renal impairment (caused by platinum-based chemotherapy), and marrow dysfunction (from metastases, chemotherapy, and/or radiation therapy). Several peri- and intra-operative strategies can be used to optimize patient management and minimize blood loss related to surgery...
May 18, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28527674/analysis-of-full-coding-sequence-of-the-tp53-gene-in-invasive-vulvar-cancers-implications-for-therapy
#11
Karl Kashofer, Sigrid Regauer
OBJECTIVE: This study evaluates the frequency and type of TP53 gene mutations and HPV status in 72 consecutively diagnosed primary invasive vulvar squamous cell carcinomas (SCC) during the past 5years. METHODS: DNA of formalin-fixed and paraffin embedded tumour tissue was analysed for 32 HPV subtypes and the full coding sequence of the TP53 gene, and correlated with results of p53 immunohistochemistry. RESULTS: 13/72 (18%) cancers were HPV-induced squamous cell carcinomas, of which 1/13 (8%) carcinoma harboured a somatic TP53 mutation...
May 17, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28527673/minimal-access-surgery-compared-to-laparotomy-for-secondary-surgical-cytoreduction-in-patients-with-recurrent-ovarian-carcinoma-perioperative-and-oncologic-outcomes
#12
Ane Gerda Z Eriksson, Ashley Graul, Miao C Yu, Anthony Halko, Dennis S Chi, Oliver Zivanovic, Ginger J Gardner, Yukio Sonoda, Richard R Barakat, Nadeem R Abu-Rustum, Mario M Leitao
OBJECTIVES: To assess the perioperative outcomes of minimal access surgery (MAS) in secondary surgical cytoreduction (SSCR) for recurrent epithelial ovarian cancer (ROC); to compare oncologic outcomes with laparotomy (LAP). METHODS: Using an institutional database, we identified all patients with ROC undergoing SSCR from 1/5/09-6/14/14. Selection for MAS or LAP was based on surgeon preference. To minimize selection bias, preoperative imaging was reviewed for all LAP cases...
May 17, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28527672/quality-of-life-among-long-term-survivors-of-advanced-stage-ovarian-cancer-a-cross-sectional-approach
#13
Susan K Lutgendorf, Eileen Shinn, Jeanne Carter, Susan Leighton, Keith Baggerly, Michele Guindani, Bryan Fellman, Marianne Matzo, George M Slavich, Marc T Goodman, William Tew, Jenny Lester, Kathleen M Moore, Beth Y Karlan, Douglas A Levine, Anil K Sood
PURPOSE: Long-term survival of women with advanced-stage ovarian cancer is relatively rare. Little is known about quality of life (QOL) and survivorship concerns of these women. Here, we describe QOL of women with advanced-stage ovarian cancer surviving for 8.5 years or longer and compare women with 0-1 recurrence to those with multiple recurrences. METHODS: Participants (n=56) recruited from 5 academic medical centers and the Ovarian Cancer Research Fund Alliance completed surveys regarding QOL (FACT-O), mood (CESD), social support (SPS), physical activity (IPAQ-SF), diet, and clinical characteristics...
May 17, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28526168/extended-mesometrial-resection-emmr-surgical-approach-to-the-treatment-of-locally-advanced-cervical-cancer-based-on-the-theory-of-ontogenetic-cancer-fields
#14
Benjamin Wolf, Roman Ganzer, Jens-Uwe Stolzenburg, Bettina Hentschel, Lars-Christian Horn, Michael Höckel
BACKGROUND: Based on ontogenetic-anatomic considerations, we have introduced total mesometrial resection (TMMR) and laterally extended endopelvic resection (LEER) as surgical treatments for patients with cancer of the uterine cervix FIGO stages I B1 - IV A. For a subset of patients with locally advanced disease we have sought to develop an operative strategy characterized by the resection of additional tissue at risk for tumor infiltration as compared to TMMR, but less than in LEER, preserving the urinary bladder function...
May 16, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28526167/significance-of-body-weight-change-during-fertility-sparing-progestin-therapy-in-young-women-with-early-endometrial-cancer
#15
Jeong-Yeol Park, Seok Ju Seong, Tae-Jin Kim, Jae Weon Kim, Duk-Soo Bae, Joo-Hyun Nam
OBJECTIVE: To evaluate the influence of body weight change during fertility-sparing progestin therapy on oncologic and reproductive outcomes in young women with early-stage endometrial cancer who did not complete child bearing. METHODS: This multicenter, retrospective study included 154 young patients with well-differentiated, endometrium-confined endometrioid endometrial adenocarcinoma on magnetic resonance imaging who received fertility-sparing progestin therapy...
May 16, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28522108/hospital-readmission-after-ovarian-cancer-surgery-are-we-measuring-surgical-quality
#16
Emma L Barber, Kemi M Doll, Paola A Gehrig
OBJECTIVES: Readmission after surgery is a quality metric hypothesized to reflect the quality of care in the index hospitalization. We examined the link between readmissions and a surrogate of surgical quality - major postoperative complication - among ovarian cancer patients. METHODS: Patients who underwent surgery for ovarian cancer between 2012 and 2013 were identified from the National Surgical Quality Improvement Project (NSQIP). Major complications were defined as grade 3 or ≥complications on the validated Claviden-Dindo scale and included both NSQIP and non-NSQIP defined complications based on readmission ICD-9 code...
May 15, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28511869/markers-of-the-p53-pathway-further-refine-molecular-profiling-in-high-risk-endometrial-cancer-a-transportec-initiative
#17
R J Edmondson, E J Crosbie, M Nickkho-Amiry, A Kaufmann, E Stelloo, H W Nijman, A Leary, A Auguste, L Mileshkin, P Pollock, H J MacKay, M E Powell, T Bosse, C L Creutzberg, H C Kitchener
BACKGROUND: The morphological classification of high-risk endometrial cancer is of limited prognostic value. Recent attempts to stratify tumours according to molecular signatures have shown considerable promise. Here we attempted to further refine molecular classifications using markers of the p53 pathway. METHODS: We analysed the expression of p53 as well as three downstream markers of the p53 pathway, p21, mdm2 and phospho-p63 (pp63), by immunohistochemistry in a series of 114 endometrial cancers (86 endometrioid, 28 non-endometrioid subtype) with high-risk features (such as high tumour grade and deep myometrial invasion) and correlated results with clinical outcome...
May 13, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28506563/challenges-to-delivery-and-effectiveness-of-adjuvant-radiation-therapy-in-elderly-patients-with-node-positive-vulvar-cancer
#18
Cameron W Swanick, Patricia J Eifel, Jinhai Huo, Larissa A Meyer, Grace L Smith
OBJECTIVE: To examine adjuvant radiation therapy (RT) use, patterns of RT delivery, and clinical outcomes in older patients with node-positive vulvar cancer. METHODS: Using SEER-Medicare linked data, we identified 444 patients (age≥66years) with node-positive squamous cell vulvar carcinoma, without distant metastases, and treated with primary surgery between 1991 and 2009. We used claims to examine RT use and the following delivery metrics: 1) completion of ≥20 fractions, 2) treatment duration <8weeks, 3) <1week of intra-treatment break, and 4) treatment interval from surgery to start of RT <8weeks...
May 12, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28501328/evaluation-of-venous-thrombosis-and-tissue-factor-in-epithelial-ovarian-cancer
#19
Joshua G Cohen, Emily Prendergast, Julia E Geddings, Ann E Walts, Hasmik Agadjanian, Yohei Hisada, Beth Y Karlan, Nigel Mackman, Christine S Walsh
OBJECTIVE: Ovarian clear cell carcinoma (OCCC) and high grade serous ovarian cancer (HGSOC) are associated with the highest risk of VTE among patients with epithelial ovarian cancer (EOC). Tissue factor (TF) is a transmembrane glycoprotein which can trigger thrombosis. We sought to evaluate if there is an association between VTE and tumor expression of tissue factor (TF), plasma TF, and microvesicle TF (MV TF) activity in this high-risk population. METHODS: We performed a case-control study of OCCC and HGSOC patients with and without VTE...
May 10, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28499649/a-seer-medicare-analysis-of-the-impact-of-metformin-on-overall-survival-in-ovarian-cancer
#20
Christine Garcia, Aaron Yao, Fabian Camacho, Rajesh Balkrishnan, Leigh A Cantrell
OBJECTIVE: Determine whether metformin use is associated with improved survival in patients with ovarian, fallopian tube or primary peritoneal cancer. METHODS: All patients with a diagnosis of first epithelial ovarian cancer from 2007 to 2011 in the combined SEER-Medicare database were identified from the SEER registry primary site codes. Comorbidities, procedures and cancer treatment ICD-9 and HCPCS codes were used to search the Medicare claims files. Medication use was determined with National Drug Codes using the Medicare Part D event files...
May 9, 2017: Gynecologic Oncology
journal
journal
23122
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"